Patents by Inventor Douglas Pippin

Douglas Pippin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10624877
    Abstract: Compositions containing imidazole-based compounds, and optionally, colloidal oatmeal, for the treatment, prevention, and management of symptoms, conditions, diseases, and disorders of the skin. Also, methods for the treatment, prevention, and management of symptoms, conditions, diseases, and disorders of the skin using compositions containing imidazole-based compounds, and optionally, colloidal oatmeal.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: April 21, 2020
    Assignee: Theraceutix, LLC
    Inventor: Douglas A. Pippin
  • Publication number: 20190367528
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: November 15, 2017
    Publication date: December 5, 2019
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • Publication number: 20180133196
    Abstract: Compositions containing imidazole-based compounds, and optionally, colloidal oatmeal, for the treatment, prevention, and management of symptoms, conditions, diseases, and disorders of the skin. Also, methods for the treatment, prevention, and management of symptoms, conditions, diseases, and disorders of the skin using compositions containing imidazole-based compounds, and optionally, colloidal oatmeal.
    Type: Application
    Filed: January 16, 2018
    Publication date: May 17, 2018
    Inventor: Douglas A. Pippin
  • Patent number: 9968590
    Abstract: Compositions containing imidazole-based compounds, and optionally, colloidal oatmeal, for the treatment, prevention, and management of symptoms, conditions, diseases, and disorders of the skin. Also, methods for the treatment, prevention, and management of symptoms, conditions, diseases, and disorders of the skin using compositions containing imidazole-based compounds, and optionally, colloidal oatmeal.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: May 15, 2018
    Assignee: Theraceutix, LLC
    Inventor: Douglas A. Pippin
  • Publication number: 20140212362
    Abstract: Compositions containing imidazole-based compounds, and optionally, colloidal oatmeal, for the treatment, prevention, and management of symptoms, conditions, diseases, and disorders of the skin. Also, methods for the treatment, prevention, and management of symptoms, conditions, diseases, and disorders of the skin using compositions containing imidazole-based compounds, and optionally, colloidal oatmeal.
    Type: Application
    Filed: March 31, 2014
    Publication date: July 31, 2014
    Applicant: THERACEUTIX, LLC
    Inventor: Douglas A. Pippin
  • Publication number: 20110177011
    Abstract: Compounds of Formula I-a and all pharmaceutically-acceptable forms thereof, are described herein. The variables R1, R2, R3, Z1, Q, and A shown in Formula I-a are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I-a, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I-a effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
    Type: Application
    Filed: January 23, 2008
    Publication date: July 21, 2011
    Inventors: Kevin S. Currie, Robert W. DeSimone, Scott A. Mitchell, Douglas A. Pippin, James W. Darrow, Xiaobing Qian, Mark Velleca, Dapeng Qian
  • Publication number: 20110160204
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Application
    Filed: February 25, 2011
    Publication date: June 30, 2011
    Applicant: CEPHALON, INC.
    Inventors: Bruce D. Dorsey, Karen L. Milkiewicz, Douglas A. Pippin, Jay P. Theroff, Ted Underiner, Linda Weinberg, Craig A. Zificsak
  • Patent number: 7919502
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: April 5, 2011
    Assignee: Cephalon, Inc.
    Inventors: Bruce D. Dorsey, Douglas A. Pippin, Jay P. Theroff, Craig A. Zificsak
  • Publication number: 20100048576
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Application
    Filed: September 24, 2009
    Publication date: February 25, 2010
    Applicant: CEPHALON, INC.
    Inventors: Bruce D. Dorsey, Karen L. Milkiewicz, Douglas A. Pippin, Jay P. Theroff, Ted Underiner, Linda Weinberg, Craig A. Zificsak
  • Patent number: 7601716
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: October 13, 2009
    Assignee: Cephalon, Inc.
    Inventors: Bruce D. Dorsey, Karen L. Milkiewicz, Douglas A. Pippin, Jay P. Theroff, Ted Underiner, Linda Weinberg, Craig A. Zificsak
  • Publication number: 20080182849
    Abstract: Compounds of Formula I and all pharmaceutically acceptable forms thereof, are described herein. The variables R1, R2, R3, Z2, and Q, shown in Formula I are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
    Type: Application
    Filed: March 26, 2008
    Publication date: July 31, 2008
    Inventors: Kevin S. CURRIE, Robert W. DeSimone, Scott A. Mitchell, Douglas A. Pippin
  • Patent number: 7405295
    Abstract: Compounds of Formula I-a and all pharmaceutically-acceptable forms thereof, are described herein. The variables R1, R2, R3, Z1, Q, and A shown in Formula I-a are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I-a, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I-a effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: July 29, 2008
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: Kevin S. Currie, Robert W. DeSimone, Scott A. Mitchell, Douglas A. Pippin, James W. Darrow, Xiaobing Qian, Mark Velleca, Dapeng Qian
  • Patent number: 7393848
    Abstract: Compounds of Formula I and all pharmaceutically acceptable forms thereof, are described herein. The variables R1, R2, R3, Z2, and Q, shown in Formula I are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: July 1, 2008
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: Kevin S. Currie, Robert W. DeSimone, Scott A. Mitchell, Douglas A. Pippin
  • Publication number: 20080032972
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Application
    Filed: April 30, 2007
    Publication date: February 7, 2008
    Applicant: Cephalon, Inc.
    Inventors: Bruce Dorsey, Karen Milkiewicz, Douglas Pippin, Jay Theroff, Ted Underiner, Linda Weinberg, Craig Zificsak
  • Patent number: 7312341
    Abstract: A novel composition comprises a compound of Formula 1 the pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixtures thereof. The composition is of particular utility in the treatment of kinase-implicated disorders.
    Type: Grant
    Filed: September 9, 2003
    Date of Patent: December 25, 2007
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: Robert W. DeSimone, Douglas A. Pippin, James W. Darrow, Scott A. Mitchell, Kevin S. Currie
  • Patent number: 7259164
    Abstract: Certain substituted imidazo[1,2-a]pyrazines and the pharmaceutically acceptable salts thereof, are provided herein. Pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable salt of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder are disclosed. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agents.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: August 21, 2007
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: Scott A. Mitchell, Robert W. DeSimone, James W. Darrow, Douglas A. Pippin, M. Diana Danca
  • Patent number: 7189723
    Abstract: This invention pertains to compounds of Formula I: and all pharmaceutically-acceptable forms thereof. The variables R1, R2, R3, Z1, Z2, W, and X shown in Formula I are defined herein. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including of breast neoplasma, endometrial cancer, colon cancer, and neck squamous cell carcinoma.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: March 13, 2007
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: Scott A. Mitchell, Kevin S. Currie, Robert W. DeSimone, Douglas A. Pippin
  • Patent number: 7160885
    Abstract: This invention pertains to compounds of Formula I: and the pharmaceutically-acceptable forms thereof. The variables R1, R2, R3, Z1, Z2, W, and X shown in Formula I are defined herein. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to Hsp90 complex modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including chronic myeloid leukemia, melanoma, breast, ovarian, brain, thyroid, colorectal, prostate, and bladder cancer, heart disease, stroke, autoimmune/inflammatory diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: January 9, 2007
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: Kevin S. Currie, Robert W. DeSimone, Douglas A. Pippin, James W. Darrow, Scott A. Mitchell
  • Publication number: 20060229337
    Abstract: At least one chemical entity chosen from compounds of Formula 2 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    Type: Application
    Filed: March 9, 2006
    Publication date: October 12, 2006
    Inventors: David Brittelli, Kevin Currie, James Darrow, Jeffrey Kropf, Seung Lee, Steven Gallion, Scott Mitchell, Douglas Pippin, Peter Blomgren
  • Publication number: 20060211738
    Abstract: Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma.
    Type: Application
    Filed: January 13, 2006
    Publication date: September 21, 2006
    Inventors: Scott Mitchell, Mihaela Danca, Peter Blomgren, Robert DeSimone, Douglas Pippin